Biomarker-Restricted Indication Urged For AstraZeneca’s Lynparza In First-Line Prostate Cancer
Executive Summary
Eleven of 13 members of the Oncologic Drugs Advisory Committee favor limiting olaparib’s use with abiraterone in metastatic castration-resistant prostate cancer to patients with tumors that carry the BRCA mutation, a subgroup that represented only 11% of the patients in the PROpel study.